FDA approves Jemperli for mismatch repair-deficient solid tumors

FDA approves Jemperli for mismatch repair-deficient solid tumors

The FDA granted accelerated approval to dostarlimab-gxly for adults with mismatch repair-deficient recurrent or advanced solid tumors that progressed on or after prior treatment and who have no satisfactory alternative therapies.An estimated 14% of solid tumors diagnosed in the United States are mismatch repair deficient. This biomarker — most often found in endometrial, colorectal and other gastrointestinal cancers — has been shown to predict response to immune checkpoint blockade with PD-1 therapy.Dostarlimab-gxly (Jemperli, GlaxoSmithKline) — a PD-1-blocking antibody —Read More

Share on facebook
Share on twitter
Share on linkedin